ACM
IMNM icon

Aster Capital Management’s Immunome IMNM Stock Holding History

Aster Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-118
Closed -$794 – 1045
2026
Q1 		$794 Sell
118
-5,511
-98% -$123K ﹤0.01% 788
2025
Q4 		$121K Buy
+5,629
New +$98.8K 0.05% 320
2025
Q2 		– Sell
-114
Closed -$1.07K – 1293
2025
Q1 		$1.07K Sell
114
-213
-65% -$2.04K ﹤0.01% 1187
2024
Q4 		$3.47K Buy
+327
New +$3.95K ﹤0.01% 906

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Aster Capital Management's IMNM Position: Q2 2026 in Review

Aster Capital Management sold out of Immunome (IMNM) in Q2 2026, closing a stake of 118 shares — an estimated $794 sold.

Aster Capital Management first reported a position in IMNM in Q4 2024 and held it in 4 quarters. The position peaked at $121K in Q4 2025. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Aster Capital Management reported no remaining Immunome position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 118 Immunome shares in Q2 2026, an estimated $794.
  • Aster Capital Management first reported a position in Immunome in Q4 2024 and held it in 4 quarters.
  • Aster Capital Management's Immunome position peaked at $121K in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.